Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673417 | 0.87 | CYP2C9 (0.53) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL13615359 | 0.85 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL21981602 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL4343263 | 0.82 | BACE1 (0.52) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL16060188 | 0.81 | HTT (0.59) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL16061971 | 0.80 | ALDH1A1 (0.49) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL16060814 | 0.78 | MEN1 (0.50) | RXFP1MAPTMEN1KMT2ADHODH | |
| SCHEMBL20659684 | 0.78 | KDM2B (0.47) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL21713073 | 0.76 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL14711206 | 0.73 | CA1 (0.53) | RXFP1KDM4EMEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2988743-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014145873-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | CYP1A2 3323/4885CYP2C9 3395/4885CYP2C19 3221/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | CYP1A2 2807/4885CYP2C9 3136/4885CYP2C19 3151/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | CYP1A2 3208/4885CYP2C9 3245/4885CYP2C19 3193/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | CYP1A2 3208/4885CYP2C9 3245/4885CYP2C19 3193/4885 |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR4, LPAR3 | CYP1A2 3305/4885CYP2C9 3235/4885CYP2C19 3229/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | CYP1A2 3208/4885CYP2C9 3245/4885CYP2C19 3193/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | CYP1A2 3323/4885CYP2C9 3395/4885CYP2C19 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.